title: Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis.
authors.affiliation: Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, Siena University, Viale Bracci 1, 53100 Siena, Italy.
authors.forename: Giacomo Maria
authors.initials: GM
authors.lastname: Guidelli
authors.forename: Sara
authors.initials: S
authors.lastname: Tenti
authors.forename: Antonella
authors.initials: A
authors.lastname: Fioravanti
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D004802:Eosinophilia / Q000139:chemically induced*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept